Literature DB >> 6428928

On the social cost of asthma.

S Thompson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6428928

Source DB:  PubMed          Journal:  Eur J Respir Dis Suppl        ISSN： 0106-4347


× No keyword cloud information.
  4 in total

Review 1.  Inhaled fluticasone propionate. A pharmacoeconomic review of its use in the management of asthma.

Authors:  H M Lamb; C R Culy; D Faulds
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

2.  Using clinical measures of disease control to reduce the burden of asthma.

Authors:  E D Bateman
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

3.  Healthcare utilisation and costs associated with adding montelukast to current therapy in patients with mild to moderate asthma and co-morbid allergic rhinitis: PRAACTICAL study.

Authors:  Roberto Dal Negro; Peter Piskorz; Roberto Vives; Magda Guilera; Vasilisa Sazonov Kocevar; Xavier Badia
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

4.  Assessment of asthma severity in adults with ever asthma: A continuous score.

Authors:  Lucia Calciano; Angelo Guido Corsico; Pietro Pirina; Giulia Trucco; Deborah Jarvis; Christer Janson; Simone Accordini
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.